Research programme: skin cancer therapeutics - Cipher Pharmaceuticals

Drug Profile

Research programme: skin cancer therapeutics - Cipher Pharmaceuticals

Alternative Names: ISC 4; MXO-005; Nanolipolee-007; PB 1SC; Sela-1-GSH; Selanocoxib

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Penn State Research Foundation
  • Developer Cipher Pharmaceuticals
  • Class Amines
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Mitogen-activated protein kinase inhibitors; Proto oncogene protein b raf inhibitors; STAT transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Malignant melanoma
  • No development reported Skin cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Skin-cancer in Canada
  • 09 Jan 2015 Cipher Pharmaceuticals has patent protection for compounds for the treatment of Malignant melanoma and other Skin cancers
  • 09 Jan 2015 Cipher Pharmaceuticals acquires all assets, including seven preclinical compounds for the treatment of Malignant melanoma and other Skin cancers from Melanovus Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top